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Adenoviruses use virus-associated RNA I (VAI RNA) to counteract the cellular antiviral response mediated
by the interferon-induced, double-stranded-RNA-activated protein kinase PKR. VAI RNA is a highly struc-
tured small RNA which consists of two long duplex regions connected at the center by a complex, short
stem-loop. This short stem-loop and the adjacent base-paired regions, referred to as the central domain, bind
to PKR and inactivate it. Currently it is not known whether binding of VAI RNA to PKR is dependent solely
on the secondary (and tertiary) structure of the central domain or whether nucleotide sequences in the central
domain are also critical for this interaction. To address this question, 54 VAI mutants with single-base
substitution mutations in the central domain of the RNA were constructed, and their capacities to inhibit the
autophosphoryation of PKR in vitro were determined. It was found that although about half of the mutants
inhibited PKR activity as efficiently as the wild type, a significant number of mutants lost the inhibitory activity
substantially, without a perceptible change in their secondary structures. These results indicate that, in
addition to secondary structure, at least some nucleotides in the central domain may be critical for the efficient
function of VAI RNA.
The interferon-induced, double-stranded RNA (dsRNA)-
activated protein kinase PKR (also referred to as p68 kinase,
eukaryotic initiation factor 2 [eIF-2] alpha kinase, and DAI) is
a ribosome-bound latent protein kinase that cells use as a
defense against infection by viruses. PKR is activated upon
infection of cells with viruses, and the activated enzyme phos-
phorylates the alpha subunit of the protein synthesis initiation
factor eIF-2. The phosphorylated eIF-2 is unable to recycle
during protein synthesis; as a result, protein synthesis comes to
a halt (reviewed in references 11 and 25). Viruses have devel-
oped diverse strategies to counteract this cellular antiviral re-
sponse; the best studied is that used by adenoviruses (Ad)
(reviewed in references 16, 17, 27, and 30). Human Ad syn-
thesize large amounts of an RNA polymerase III-directed,
low-molecular-weight RNA designated virus-associated RNA I
(VAI RNA). It is a 160-nucleotide (nt), highly structured RNA
with two long duplex regions connected at the center by a
complex, short stem-loop. The central short stem-loop and the
adjacent base-paired regions are referred to as the central
domain. Cells infected with Ad mutants with the VAI RNA
gene deleted are defective in translation and have high levels
of PKR activity and phosphorylated eIF-2 (26, 28, 29, 32). VAI
RNA binds to and irreversibly inactivates PKR and thereby
protects and maintains the eIF-2 activity (4, 8, 12, 14, 22). The
structural requirements of VAI RNA for its function have
been investigated by introducing deletions and linker-scan and
base-compensatory substitutions into the VAI RNA and ana-
lyzing such mutants in vivo in virus infections and transient
assays and also in vitro for their capacities to bind to and block
the autophosphorylation activity of PKR (1, 4, 5, 7, 8, 19–21,
24). These studies showed that mutant molecules would retain
function as long as the integrity of the central domain was
maintained. Only those molecules which underwent even a
small alteration in the structure of the central domain failed to
function in vivo and in vitro, indicating that the central domain
is the most critical part of the molecule.
The in vivo target of the VAI RNA, PKR, has also been
examined extensively by several investigators (9, 13, 18, 23).
These studies indicate that both the inhibitor VAI RNA and
the activator dsRNA bind to the same region of PKR. This
raises an important question as to how the VAI RNA, which
has a structure dramatically different from that of dsRNA,
interacts with PKR. Because binding of VAI RNA to PKR
correlates with function and because the integrity of the central
domain is critical for its function, we asked whether interaction
of VAI RNA with PKR is based solely on the secondary struc-
ture of the central domain or whether nucleotide sequences
within the central domain are also critical for this interaction.
In other words, is it possible to construct VAI mutants with
mutations in the central domain that are compromised for
function without detectable alterations in the secondary struc-
ture of the central domain? Because there is very little detect-
able sequence homology between the nucleotide sequences of
VAI RNAs of different serotypes (15), the nucleotide se-
quences of the VAI RNA have not been considered to be
important for function. The role of nucleotide sequences could
not be addressed in previous mutagenesis studies because the
functionally defective mutants that have altered nucleotide
sequences in the central domain also have an altered central
domain structure. In this study, we introduced 54 single-base
substitution mutations into the central domain of VAI RNA
and analyzed the capacities of the mutants to function in vitro.
Surprisingly, we found that a significant number of these sub-
stitution mutants failed to function efficiently, even though
their secondary structures were intact. These studies suggest
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that, in addition to recognizing the structure, PKR may also
recognize certain nucleotide sequences within the context of
the secondary structure of the central domain.
MATERIALS AND METHODS
Construction of the single-base substitution mutations in the central domain.
pT7VA is a plasmid in which the DNA sequences coding for the Ad type 5 (Ad5)
VAI gene were cloned downstream of the T7 promoter. At the 39 end, the VAI
coding sequences terminate with an EcoRI site (6). When the EcoRI-linearized
pT7VA is transcribed in vitro with T7 RNA polymerase, it produces an RNA
with an authentic 59 end and four U residues at the 39 end, followed by a G
residue which is a part of the EcoRI recognition sequence. The VAI coding
sequences contain CspI and BstEII sites at positions 161 and 199, respectively,
and a newly introduced EcoRI site at position 1160 (all numbering is based on
a G start [31]). Nucleotide sequences between positions 161 and 199 were
mutated by the substitution of DNA sequences of pT7VA between CspI and
BstEII sites with the synthetic double-stranded oligonucleotides with single-base
substitutions at the positions indicated in the names of the mutants. Similarly,
nucleotides between positions199 and1160 were mutated by the substitution of
synthetic double-stranded oligonucleotides between the BstEII and EcoRI sites.
The mutations were confirmed by DNA sequence analysis. All DNA manipula-
tions were carried out by using standard recombinant DNA technology.
Purification and in vitro phosphorylation of PKR. PKR was purified by sub-
jecting the ribosomal salt wash to successive chromatographies on DEAE-cellu-
lose, Mono S, and hexylamine agarose columns. Further details of this purifica-
tion scheme can be obtained from reference 7. Autophosphorylation of PKR was
carried out in a 50-ml reaction mixture consisting of 10 ml of partially purified
PKR obtained from the hexylamine agarose column fraction, 20 mM Tris-HCl
(pH 7.5), 2 mM 2-mercaptoethanol, 4 mM magnesium acetate, 10 mCi of
[g-32P]ATP (specific activity, 30 Ci/mmol; New England Nuclear Corp.), 2 mg of
reovirus RNA per ml as dsRNA, and various concentration of VAI RNAs, as
indicated in the figures. The reaction mixture was incubated for 30 min at 308C,
and the reaction was terminated by the addition of 50 ml of 23 sodium dodecyl
sulfate (SDS) sample buffer (0.125 M Tris-HCl [pH 6.8], 4% SDS, 20% glycerol,
10% 2-mercaptoethanol). The reaction mixture was boiled for 5 min, and phos-
phorylated polypeptides were analyzed on SDS–12.5% polyacrylamide gels with
prestained molecular weight markers (Sigma catalog no. SDS-7B). Dearing
strain reovirus type 3 was used for the preparation of reovirus RNA (7).
FIG. 1. Secondary structure models of VAI RNA. (A) Structure originally proposed by Furtado et al. (6) and Mellits and Mathews (20); (B) revised secondary
structure proposed by Clark et al. (4, 5). A to D refer to looped sequences.
4300 RAHMAN ET AL. J. VIROL.
 o
n
 M
arch 8, 2017 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
Preparation of mutant and WT VAI RNAs and in vitro PKR block assays.
Plasmids containing wild-type (WT) or mutant VAI genes were transcribed in
vitro by using T7 RNA polymerase as described previously (7) with an in vitro
transcription kit (Riboprobe II core system; Promega catalog no. P2590). The
RNA samples were gel purified by electrophoresis on a 6% native polyacryl-
amide gel before use. The hexylamine agarose column fraction was preincubated
at 308C for 10 min with in vitro-transcribed VAI RNA prior to the addition of
dsRNA and [g-32P]ATP. The phosphorylated proteins were analyzed on SDS–
12.5% polyacrylamide gels (7).
Secondary structure analysis. The secondary structures of the mutant RNAs
were analyzed exactly as described previously (6). WT and mutant VAI genes
were transcribed in vitro, and the RNAs were end labeled at the 39 end with
32P-labeled pCp, gel purified, and partially digested with single-strand-specific
RNases T1, U2, and BC, such that the majority of the molecules were not
digested and the rest were cleaved only once. The cleavage products were then
resolved on 14% DNA sequencing gels.
RESULTS
Introduction of single-base substitution mutations in the
central domain of VAI RNA. The experimentally derived sec-
ondary structure model of VAI RNA consists of two long
imperfectly base-paired regions (stems I and III) connected at
the center by a perfectly base-paired short duplex region (stem
II) (Fig. 1A). In this structure, nucleotide sequences in three
regions form loops, the first from nt 23 to 30 (loop A), the
second from nt 62 to 70 (loop B), and the third from nt 103 to
117 (loop C). Nucleotides between nt 80 and 117 fold to form
a complex, short stem-loop structure, which includes stem IV
and loop C, and a minor loop, loop D, from nt 122 to 127. The
central portion of the molecule, which consists of the short
stem-loop and the adjacent base-paired sequences, is referred
to as the central domain. Because alternate base pairing is
possible in the region between nt 91 and 128, the determina-
tion of a precise structure for this region has been difficult and
alternative secondary structures have been proposed (5, 15,
24). A structure recently proposed by Clark and coworkers is
shown in Fig. 1B (4, 5). In this structure, the short stem-loop of
the central domain is shifted to a position slightly higher than
that shown in Fig. 1A. This is because the nucleotide sequence
ACCC between residues 118 and 123, which is conserved in
VAI RNAs of different serotypes, is allowed to base pair with
the nucleotide sequence GGGU between residues 36 and 41
(15). As a result, the nucleotides between nt 90 and 115 form
a short stem-loop. In addition, a minor loop interrupts stem II
at nt 122. Both structures are compatible with the single-
strand-specific RNase digestion patterns (6, 20). Therefore, at
present it is difficult to determine unambiguously which of the
two structures is accurate. In addition, some of our mutational
analyses are not consistent with the structure shown in Fig. 1B
(7) (see Discussion). In this paper, we interpret our data on the
basis of the secondary structure model shown in Fig. 1A. In
Discussion, we also interpret our data on the basis of the
secondary structure model shown in Fig. 1B.
All previous mutational analyses of VAI RNA used large
mutations. Such mutations always affected the precise folding
of the molecule in the central domain. To assess the impor-
tance of the nucleotide sequence in the function of the RNA,
it was necessary to introduce single-base substitutions which, it
was hoped, would not alter the secondary structures. There-
fore, we introduced 54 single-base substitutions in the 39 region
of the central domain by an approach detailed in Materials and
Methods. Of these, 12 mutations are transitions and the rest
are transversions. The entire coding sequence of each mutant
VAI gene was sequenced to confirm that the newly introduced
base substitution was the only mutation in the entire coding
sequence. Three of the four conserved nucleotides (nt 119,
120, and 121) were mutated twice. Figure 2 shows the locations
of these mutations in the secondary structure of the central
domain of the WT VAI RNA.
In vitro inhibition of autophosphorylation of PKR by mu-
tant VAI RNAs.We recently showed that the in vivo properties
of the VAI mutants can be faithfully reproduced in vitro (7). In
this study, a considerably purified PKR preparation from HeLa
cells was preincubated with in vitro-transcribed WT or mutant
VAI RNAs that were previously tested for their function in
vivo in the context of the viral chromosome. Reovirus RNA
was then added as an activator along with [g-32P]ATP, to allow
the enzyme to autophosphorylate in vitro. Phosphorylation of
PKR was then quantitated by subjecting the radiolabeled
polypeptides to SDS-polyacrylamide gel electrophoresis. Un-
der our assay conditions, we have found that at low concen-
trations of VAI RNAs, mutants that failed to function in vivo
uniformly failed to block the autophosphorylation (activation)
of PKR in vitro, whereas mutants that were phenotypically WT
in vivo inhibited the autophosphorylation of PKR in vitro ef-
ficiently. We used these assay conditions to determine the
capacities of the mutant VAI RNAs to inhibit the autophos-
phorylation activity of PKR. All mutant VAI RNAs were as-
sayed at least three times, and the majority of the mutants were
tested four or five times. The average percent inhibitions of
PKR activity (with error bars) for these mutants are shown in
a bar diagram in Fig. 3.
On the basis of their capacities to inhibit the activation of
PKR in vitro, the mutants can be classified into three groups.
The first group consists of those which inhibit PKR activity as
efficiently as the WT VAI RNA. Most of these mutations are
clustered between nt 90 and 118 (proximal part of stem III,
stem IV, and loop C). Apparently, these mutations do not
induce alterations in the secondary structures that would be
detrimental to function. These results also suggest that these
bases are not critical for the PKR-VAI RNA interactions. The
second group of mutants show an intermediate phenotype in
that the mutations in these VAI RNA molecules lead to a
FIG. 2. Single-base substitutions in the central domain of VAI RNA. The
letters shown in the dark format are the WT sequence. Mutations are shown in
light format. The bases numbered represent nucleotides from the 59 end of the
RNA, with G as the starting residue (31). Bases 118, 119, 120, and 121 are
mutated twice.
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moderate loss of activity, ranging from 20 to 50%. These mu-
tations include nucleotides in the lower part of stem IV and in
loop D and the bases that pair in the duplex regions of stem III
and stem I. The third group of mutants are severely defective
in vitro and include those with mutations at nt 91 (pm91), 111
(pm111), 132 (pm132), and 135 (pm135). These mutant RNAs,
at a concentration of 0.1 mg/ml, lost about 60 to 100% of
activity. With the exception of pm132, none of these mutations
induce detectable alterations in the secondary structure of the
central domain (see below). Thus, it seems that these residues
are critical for the binding of PKR to VAI RNA, and the
results suggest that PKR-VAI RNA interaction may involve
some degree of nucleotide sequence specificity.
Analysis of the secondary structures of the mutant RNAs.
An important consequence of the mutations in an RNA is the
loss of secondary structure, which would also potentially have
an impact on the tertiary structure. Because previous studies
have shown that even a minor alteration in the secondary
structure of the central domain can lead to loss of function, we
have analyzed the secondary structures of the mutant RNAs of
FIG. 3. Bar diagrams showing the capacities of the mutant VAI RNAs to block the autophosphorylation of PKR activity in vitro. Mutant or WT VAI genes were
transcribed in vitro with T7 RNA polymerase, gel purified with a native polyacrylamide gel, and incubated with a partially purified PKR from HeLa suspension cultures
(7). The radiolabeled polypeptides were resolved in an SDS–12% polyacrylamide gel, and the radioactive PKR band was quantitated by a laser densitometer and
plotted. The samples were assayed at least three times and in most cases four or five times. Values shown on the y axis correspond to the percent activity of PKR
remaining compared with that in control experiments in which autophosphorylation was carried out without VAI RNA. Control values were taken as 100%. Error bars
indicate deviations from average values.
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pm91, pm111, pm119b, pm120b, pm121b, pm132, and pm135.
The mutant VAI genes were transcribed in vitro, labeled at
their 39 ends with [32P]pCp, and then digested with low con-
centrations of single-strand-specific RNases T1 (cleaves after
G), BC (cleaves after pyrimidines), and U2 (cleaves after A)
such that less than 10% of the molecules were digested with
RNases and each molecule in the digested portion was cleaved
only once. The digests were then analyzed on 14% DNA se-
quencing gels with ladder markers generated by treating the
same RNAs with alkali (6). The nuclease digestion patterns of
these RNAs are shown in Fig. 4. Some of the patterns are faint
in this figure, but they have been repeated to confirm the
cleavages. We and others have used this approach previously
to predict the folding of the mutant VAI RNAs (6, 8, 21, 24).
The results presented in Fig. 4 suggest that all of the RNAs,
with the exception of that of pm132, show cleavage patterns
identical to that of WT RNA, including those specific for the
central domain, suggesting that these RNAs retain their native
secondary structures. For example, G (Fig. 4, lanes T1)-, py-
rimidine (lanes BC)-, and A (lanes U2)-specific cleavages for
the sequence CAGGUG between nt 121 and 128 are present in
all mutants except pm132 and also in identical locations in the
autoradiogram. Note that an additional strong G cleavage in
the case of pm119b at nt 119 is due to the G substitution in this
position. Similarly, cleavages specific for the sequence UACCG
between nt 102 and 109 are also present in the RNAs of pm91,
pm111, pm119b, pm120b, pm121b, and pm135. The pattern ob-
tained for pm132 is somewhat difficult to interpret. A careful
examination of this pattern indicates that the entire pattern is
shifted to a slightly lower position in the gel including loop
B-specific cleavages around nt 64. Clearly, this RNA has un-
dergone some structural alterations which may account for the
loss of activity. This result also suggests that even a minor
alteration in the secondary structure can be detected in this gel
system. In summary, these results suggest that several of these
point mutants retain their native secondary structures yet lose
the capacity to inhibit the autophosphorylation activity of
PKR.
DISCUSSION
Currently, the only known function of VAI RNA in Ad
infection is to block the autophosphorylation of PKR and thus
protect the host-cell translation apparatus. The VAI RNA
binds to PKR and inactivates it. To study the structural re-
quirements for the VAI RNA to bind to PKR, our group and
also that of Mathews have mutagenized the RNA extensively
and analyzed it in vivo (both in the context of viral chromo-
some and in transient assays) and also in vitro for its capacity
to bind to and block the autophosphorylation of PKR (1, 6, 7,
19–21, 24). Although there are some minor differences be-
tween the results of the two laboratories, in general these
results indicate that the VAI RNA binding to PKR correlates
with function and that the central domain and the proximal
part of the apical stem are the critical parts of the molecule
both for function and for binding. Studies have also shown that
both VAI RNA and dsRNA bind to the N-terminal 171 amino
acids of PKR, and mutational analysis of this region has indi-
cated that amino acids critical for the binding of dsRNA are
also critical for the binding of VAI RNA, suggesting that both
the activator and the inhibitor bind to the same region in the
protein (9, 13, 18, 23). These and other results suggest that
PKR can be activated by any RNA as long as the RNA is
perfectly double stranded in nature. On the other hand, bind-
ing and inactivation of PKR would involve a specific secondary
or tertiary structure in VAI RNA. This suggests that there may
be subtle differences in the interactions of PKR with VAI RNA
and with dsRNA. The purpose of this study was to determine
whether interaction of VAI RNA with PKR is based solely on
the secondary (and tertiary) structure in the central domain or
whether there are nucleotide sequences within this central
domain that play important roles in this interaction.
To evaluate the effect of the point mutations on the function
of the RNAs, we used the in vitro autophosphorylation assay.
We recently analyzed a series of VAI mutants in vitro for their
capacities to inhibit the phosphorylation of partially purified
PKR from HeLa cells (7). Previously, these same mutants were
rebuilt into the viral chromosome and were examined for their
phenotypes in a variety of assays, including viral polypeptide
synthesis, growth yield, and PKR activation (1, 6). When a low
concentration of these same mutant VAI RNAs was used in
the PKR block assays in vitro, the mutants that failed to func-
FIG. 3—Continued.
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tion in vivo uniformly failed to inhibit autophosphorylation of
PKR (7), showing excellent correlation between in vivo and in
vitro phenotypes. Thus, in our hands, the in vitro inhibitory
activity of the mutant VAI RNAs is a very good predictor of
the in vivo phenotype. In addition, in our in vitro assays, only
VAI RNA can inhibit the activation of PKR at concentrations
of 0.1 to 0.2 mg/ml. Other small RNAs, such as Epstein-Barr
virus-encoded small RNAs (EBERs), Tar RNA, and VAII
RNA, require a much higher (50-fold more) concentration of
RNA for the inhibition to be detected (8a), consistent with
their poor capacities to complement for the function of VAI
RNA in vivo (2, 3, 10, 16).
In the study reported here, we analyzed the 54 single-base
substitution mutants in vitro by using the same-quality enzyme
used in our previous studies (7). Thirty of the 54 single-base
substitutions introduced into the central domain of the VAI
RNA produce mutants that can block the autophosphorylation
of PKR as efficiently or nearly as efficiently as the WT RNA.
On the basis of the secondary structure shown in Fig. 1A, these
mutations mostly lie in the proximal part of the apical stem, the
59 portion of the short stem-loop, and loop C. We draw two
conclusions from these results. First, these mutations did not
induce structural alterations in the central domain to the ex-
tent that the alterations would impinge on the function of the
RNA. Second, these nucleotides are not critical for VAI RNA-
PKR interactions. It is surprising that almost all nucleotides in
loop C can be mutated, although one at a time, without causing
loss of activity. This shows that these residues may not be
directly involved in the PKR interactions. Perhaps these se-
quences exist as a loop to allow the folding of the central
domain in a configuration that is optimal for function.
Mutageneses of nt 91, 95, 96, and 111 and of most of the
nucleotides between nt 118 and 138 affect function signifi-
cantly, and in some cases the effect is quite severe. The loca-
FIG. 4. Single-strand-specific RNase cleavage analysis of WT and point mutant VAI RNAs. In vitro-synthesized RNAs were labeled at the 39 ends (as described
in Materials and Methods) and digested with RNases T1, BC, and U2. The products were resolved in 14% DNA sequencing gels. M, ladders generated by partial
digestion of the labeled RNA under alkaline conditions (6). Numbers 23, 64, 106, and 124 refer to nucleotides from the 59 end of WT VAI RNA. Cleavages in regions
23, 64, and 106 to 124 belong to loop A, loop B, and the short stem-loop of the central domain, respectively.
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tions of these mutations are shown in Fig. 5A. The severely
defective mutants are pm91, pm111, and pm132, which retain
less than 25% of the inhibitory activity of WT VAI RNA.
Other defective mutants retain about 50 to 80% of the inhib-
itory activity. One obvious consequence of introducing muta-
tions, however small they are, is the alteration of the secondary
structure. Even a small mutation can affect the secondary
structure in the central domain and thus reduce or abolish
activity. Surprisingly, we did not detect any alteration in the
secondary structures for these defective mutants, except for
pm132. All cleavages specific to the central domain of the WT
RNA are detected in the mutant RNAs that we tested, and
none of the cleavage patterns except that of pm132 warrants a
new structure. Normally, this gel system is sensitive to even a
minor change in the secondary structure, as evident from the
results for pm132. The nucleotides between nt 127 and 133
belong to the perfectly base-paired duplex region (stem II) of
the central domain. It is conceivable that this duplex region is
very crucial for the PKR interaction with VAI RNA and that a
single base mismatch in this region may be deleterious for its
function (see below). It is also interesting to note here that we
previously constructed and analyzed two nondefective VAI
mutants (sub707 and sub708 [1, 6–8]) in which most of the loop
A sequences are mutated without loss of activity, suggesting
that nucleotide sequences in loop A may also not be critical for
VAI RNA function. In summary, these point mutants collec-
tively define a class of mutants which retain the secondary
structure and yet lose biological activity, suggesting that per-
haps there is some degree of nucleotide sequence specificity
involved in the VAI RNA function.
Several secondary structures have been proposed for the
central domain (4, 5, 15, 24); the one most recently proposed
is shown in Fig. 1B (4, 5). In this structure, the short stem-loop
of the central domain is positioned slightly higher than that
proposed in the original structure (Fig. 1A). This is primarily
because the conserved nucleotides ACCC between nt 118 and
123 are allowed to base pair with nucleotides between nt 36
and 41. While this structure is also compatible with nuclease
sensitivity analysis, some of the mutational analysis is not con-
sistent with this model structure (7). We recently described a
phenotypically WT mutant, VAI CB, in which mismatches in
the apical stem (stem III) were corrected to form a perfectly
base-paired stem. In this mutant, as a result of mutations, the
nucleotide sequence ACCC located between nt 118 and 123 of
the WT sequence is duplicated between nt 90 and 95, which
almost certainly would base pair with the nucleotides between
nt 36 and 41. Thus, in view of these results, it is necessary to
consider both structures as plausible at the present time. The
elucidation of a precise structure for this region will require
X-ray crystallographic data.
When the point mutants are considered in light of the re-
vised structure shown in Fig. 1B, it appears that most of the
nucleotides of the short stem-loop (stem IV and loop C) do not
appear to be critical for function (Fig. 5B). Because mutations
in stem IV lead to perturbations in the base-paired structure
and because such mutations did not affect function, these re-
sults suggest that function is not dependent on the base-paired
region of stem IV. On the other hand, most of the mutations
cluster in the duplex regions in the central domain that connect
two long stems, stem I and stem III. These results are consis-
tent with the interpretation that perfectly base-paired duplex
regions in this region may be critical for PKR interaction with
VAI RNA.
Currently it is possible only to speculate on the precise
mechanism by which VAI RNA intercedes in the autophos-
phorylation of PKR. As stated above, studies have shown that
both dsRNA and VAI RNA bind to the same region of PKR.
It has been suggested that the duplex region of the apical stem
proximal to the central domain and stem II (both structures)
interact with PKR in a manner similar to the interaction of
dsRNA with PKR, although the short stem-loop of the central
domain would prevent activation of the kinase (4). Another
possibility is that the PKR would interact with two stems but
the PKR activation by VAI RNA would be prevented because
FIG. 5. Locations of mutations in the central domain which result in significant loss of PKR-inhibitory activity. (A) Mutations shown in the context of the secondary
structure shown in Fig. 1A. (B) Mutations shown in the context of the revised secondary structure shown in Fig. 1B.
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the two stems do not lie on a single helical axis. Both mecha-
nisms attach importance to the duplex regions in the central
domain (4).
Why do many of the point mutations cause loss of activity,
which in some cases is rather dramatic, even though the struc-
ture of the central domain in these mutants remains intact?
One possibility is that, in addition to involving the secondary
structure, PKR interactions with VAI RNA involve some de-
gree of sequence specificity. The enzyme would recognize
these critical residues in the context of the secondary structure,
and the bases that are substituted are not compatible with
interaction with PKR. The question of whether these nucleo-
tides are conserved between the VAI RNAs of different sero-
types is important here but is difficult to address. The only
nucleotide sequence homology identified between VAI RNAs
of Ad2 (or Ad5), Ad7, and Ad12 is a tetranucleotide sequence,
ACCC, that is presumed to base pair with nucleotides GGGU
between nt 36 and 41. The nucleotides identified to be impor-
tant for function in our study do not appear to be present in the
same exact locations in VAI RNAs of other serotypes (15).
Because Ad7 and Ad12 VAI RNAs can complement for the
function of Ad2 VAI RNAs, at least in transient assays (15), it
is likely that these residues, or residues similar to those iden-
tified here, may exist in similar locations in other RNAs. These
do not need to be the same nucleotide or nucleotides but could
be purines or pyrimidines at specific locations in the central
domain. However, it may not be possible to identify these
nucleotides by looking at the linear sequences of different VAI
RNAs because such nucleotides may be functionally important
only when they are presented in the context of the secondary
structure of the central domain. Because the secondary struc-
tures of the VAI RNAs of other Ad serotypes have not been
determined experimentally, it is difficult to identify the nucleo-
tides that are critical for function in VAI RNAs of other
serotypes which are also conserved. This situation becomes
even more complex when the tertiary structure of this RNA is
considered, as it is almost certain that many nucleotides of the
central domain will contribute to its tertiary structure.
Another possibility that cannot be entirely ruled out at
present is that these mutations induce perturbations in the
secondary structure that are so small that they cannot be de-
tected in our secondary structure analysis; however, such mi-
nor perturbations would be sufficient to affect their activity.
For example, perfectly base-paired stem II may be critical for
the function of VAI RNA, and single-base mutations would
perturb this duplex structure and hence compromise activity.
However, this interpretation is not adequate to explain the loss
of activity for mutants in which nt 95, 96, and 111 and nucleo-
tides between nt 121 and 126 are mutated, as these nucleotides
are not expected to pair with other nucleotides in the model
structure shown in Fig. 1A. Similarly, the loss of activity for
mutants in which nt 123, 125, 134, and 135 are mutated is not
explained, since these nucleotides are not expected to pair with
other nucleotides in the structure shown in Fig. 1B. Further-
more, the conserved nucleotides 119, 120, and 121 were mu-
tated twice, and one of the two mutations (pm119a, pm120a,
and pm121b; Fig. 2) should still maintain the duplex structure
with the G-U pair. Thus, it seems that perturbation of the
duplex regions may not be the only explanation for the loss of
activity. Rather, PKR has some preference for the nucleotides
at specific locations in the central domain. We also note that
the actual secondary structure of the central domain in solu-
tion may be slightly different from those presented in Fig. 1A
and B, in which case some of the interpretation will need to be
modified. A three-dimensional structure of this RNA will be
essential to resolve many mechanistic questions, such as the
regions of the VAI RNA that bind to PKR and the critical
residues necessary for this interaction, as well as the structural
requirements of the N-terminal region of PKR for its interac-
tion with both VAI RNA and dsRNA. Nonetheless, the avail-
ability of a systematic collection of point mutants of the central
domain of VAI RNA as described here will aid further in the
unraveling of the intricate details of the RNA-protein interac-
tions of this system.
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